Biochemical recurrence after radical prostatectomy: what does it mean?

Tourinho-Barbosa, Rafael; Srougi, Victor; Nunes‐Silva, Igor; Baghdadi, Mohammed; Rembeyo, Grégory; Eiffel, Sophie Serey; Barret, Éric; Rozet, François; Galiano, Marc; Cathelineau, Xavier; Sánchez-Salas, Rafael

doi:10.1590/s1677-5538.ibju.2016.0656

Cited by 92 publications

(67 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(20) BCR after RP is a surrogate follow-up endpoint which overall correlates poorly with progression to metastases and PCSM. (19,21,22) It is based upon PSA, which is expected to reach undetectable levels 1-3 months after RP. (19) The European Association of Urology and the American Urological Association have recommended defining BCR as a PSA ≥ 0.2 ng/mL, followed by a subsequent confirmatory level.…”

Section: Discussionmentioning

confidence: 99%

“…PSA assay non-uniformity across different laboratories is a recognised issue when comparing studies involving PSA nadirs. (19) As such, our study defined an undetectable PSA as a range of 0.01-0.1 ng/mL, which was representative of the span of various definitions of undetectable PSA levels across the different pathology companies during the period of observation. Skove defined undetectable PSA nadirs as assays < 0.01 ng/ml.…”

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Time to Prostate-Specific Antigen Nadir After Radical Prostatectomy – a new potential predictive prognostic parameter and its impact on clinical outcomes

Tran¹,

Moretti²,

O’Callaghan³

2020

Preprint

View full text Add to dashboard Cite

BackgroundTo investigate and validate previously published associations between time to prostate-specific antigen nadir and the time-to-nadir after radical prostatectomy with biochemical recurrence and to extend this analysis to overall survival and prostate cancer-specific mortality risk. MethodsThis is a retrospective analysis of 1796 men from the South Australian Prostate Cancer Clinical Outcomes Collaborative database treated with radical prostatectomy between 1998-2018 with available prostate-specific antigen nadir data within 1-6 months after surgery. Uni- and multivariable analyses of prostate-specific antigen nadir, time-to-nadir, biochemical recurrence and death were performed with Cox and competing risks models (adjusted for age, surgery year, tumour features and preoperative prostate-specific antigen).ResultsThe univariable analysis demonstrated those with shorter time-to-nadir <3 months had a decreased risk of biochemical recurrence (log-rank, p=0.0098) compared to those with longer time-to-nadir 3-6 months. For men with a time-to-nadir <3 months, a Log-rank test showed a decreased risk of prostate cancer-specific mortality (p=0.026) compared to time-to-nadir 3-6 months, without a difference in overall survival. Multivariable competing risk analyses indicated that biochemical recurrence was more likely when time-to-nadir was 3-6 months compared to <3 months (sHR=1.43, CI 1.01-2.02, p=0.04).ConclusionsAmong men undergoing radical prostatectomy, a shorter post-operative time-to-nadir <3 months is associated with decreased risk of biochemical recurrence compared to time-to-nadir 3-6 months. Following adjustment for confounders and competing risks, there was no significant difference in time-to-nadir for mortality outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Time to Prostate-Specific Antigen Nadir After Radical Prostatectomy – a new potential predictive prognostic parameter and its impact on clinical outcomes

Tran¹,

Moretti²,

O’Callaghan³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Increased PSA serum levels are commonly observed in PCa after radical prostatectomy and are defined "biochemical recurrence" [303]. Oral administration of 60 mg/day of sulforaphane for six months, followed by two months with no treatment, led to a partial reduction of PSA levels in PCa patients who underwent prostate removal [304].…”

Section: Clinical Impactmentioning

confidence: 99%

Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets

Fontana

Raimondi

Marzagalli

et al. 2020

Cells

View full text Add to dashboard Cite

Prostate cancer (PCa) represents a major cause of cancer mortality among men in developed countries. Patients with recurrent disease initially respond to androgen-deprivation therapy, but the tumor eventually progresses into castration-resistant PCa; in this condition, tumor cells acquire the ability to escape cell death and develop resistance to current therapies. Thus, new therapeutic approaches for PCa management are urgently needed. In this setting, natural products have been extensively studied for their anti-PCa activities, such as tumor growth suppression, cell death induction, and inhibition of metastasis and angiogenesis. Additionally, numerous studies have shown that phytochemicals can specifically target the androgen receptor (AR) signaling, as well as the PCa stem cells (PCSCs). Interestingly, many clinical trials have been conducted to test the efficacy of nutraceuticals in human subjects, and they have partially confirmed the promising results obtained in vitro and in preclinical models. This article summarizes the anti-cancer mechanisms and therapeutic potentials of different natural compounds in the context of PCa prevention and treatment.

show abstract

“…Patient data were collected from the electronic patient record and included age, Gleason score, TNM-classification [25], Prostate-Specific Antigen (PSA)-levels, imaging outcomes (both of the 18 F-DCFPyL PET/CT and of subsequent imaging studies), pathology results and clinical follow-up after the PSMA PET/CT scans. BCR was defined as rising PSA-values after RP, or any PSA-level 2.0 ng/mL above the nadir following EBRT, BT or HIFU [12,[26][27][28][29].…”

Section: Consecutive Patients With Bcr Scanned With 18 F-dcfpyl Pet/mentioning

confidence: 99%

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer

et al. 2020

View full text Add to dashboard Cite

Radiolabeled Prostate-Specific Membrane Antigen (PSMA) PET/CT is the current standard-of-care for lesion detection in patients with biochemically recurrent (BCR) prostate cancer (PCa). However, rigorous verification of detected lesions is not always performed in routine clinical practice. To aid future 18 F-radiolabeled PSMA PET/CT interpretation, we aimed to identify clinical/imaging characteristics that increase the likelihood that a PSMAavid lesion is malignant. Materials and methods 262 patients with BCR, who underwent 18 F-DCFPyL PSMA PET/CT, were retrospectively analyzed. The malignant nature of 18 F-DCFPyL PET-detected lesions was verified through any of the following metrics: (1) positive histopathological examination; (2) additional positive imaging; (3) a �50% decrease in Prostate-Specific Antigen (PSA) following irradiation of the lesion(s). Results In 226/262 PET scans (86.3%) at least one lesion suspicious for recurrent PCa was detected ('positive scan'). In 84/226 positive scans (37.2%), at least one independent verification metric was available. PSMA PET-detected lesions were most often confirmed to be malignant (PCa) in the presence of a CT-substrate (96.5% vs. 55.6% without CT-substrate), with SUV peak �3.5 (91.4% vs. 60.0% with SUV peak <3.5), in patients with a PSA-level �2.0

show abstract

Biochemical recurrence after radical prostatectomy: what does it mean?

Cited by 92 publications

References 44 publications

Time to Prostate-Specific Antigen Nadir After Radical Prostatectomy – a new potential predictive prognostic parameter and its impact on clinical outcomes

Time to Prostate-Specific Antigen Nadir After Radical Prostatectomy – a new potential predictive prognostic parameter and its impact on clinical outcomes

Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer

Contact Info

Product

Resources

About